Rationale: Type 2 innate lymphoid cells (ILC2s) are significant sources of type 2 cytokines, which are implicated in the pathogenesis of asthma and asthma exacerbations. The role of ILC2s in virus-induced asthma exacerbations is not well characterized. Objectives: To characterize pulmonary ILC responses following experimental rhinovirus challenge in patients with moderate asthma and healthy subjects. Methods: Patients with moderate asthma and healthy subjects were inoculated with rhinovirus-16 and underwent bronchoscopy at baseline and at Day 3, and Day 8 after inoculation. Pulmonary ILC1s and ILC2s were quantified in bronchoalveolar lavage using flow cytometry. The ratio of bronchoalveolar lavage ILC2:ILC1 was assessed to determine their relative contributions to the clinical and immune response to rhinovirus challenge. Measurements and Main Results: At baseline, ILC2s were significantly higher in patients with asthma than in healthy subjects. At Day 8, ILC2s significantly increased from baseline in both groups, which was significantly higher in patients with asthma than in healthy subjects (all comparisons P < 0.05). In healthy subjects, ILC1s increased from baseline at Day 3 (P = 0.001), while in patients with asthma, ILC1s increased from baseline at Day 8 (P = 0.042). Patients with asthma had significantly higher ILC2:ILC1 ratios at baseline (P = 0.024) and Day 8 (P = 0.005). Increased ILC2:ILC1 ratio in patients with asthma correlated with clinical exacerbation severity and type 2 cytokines in nasal mucosal lining fluid. Conclusions: An ILC2-predominant inflammatory profile in patients with asthma was associated with increased severity and duration of rhinovirus infection compared with healthy subjects, supporting the potential role of ILC2s in the pathogenesis of virus-induced asthma exacerbations.
Rationale: Type 2 innate lymphoid cells (ILC2s) are significant sources of type 2 cytokines, which are implicated in the pathogenesis of asthma and asthma exacerbations. The role of ILC2s in virus-induced asthma exacerbations is not well characterized. Objectives: To characterize pulmonary ILC responses following experimental rhinovirus challenge in patients with moderate asthma and healthy subjects. Methods: Patients with moderate asthma and healthy subjects were inoculated with rhinovirus-16 and underwent bronchoscopy at baseline and at Day 3, and Day 8 after inoculation. Pulmonary ILC1s and ILC2s were quantified in bronchoalveolar lavage using flow cytometry. The ratio of bronchoalveolar lavage ILC2:ILC1 was assessed to determine their relative contributions to the clinical and immune response to rhinovirus challenge. Measurements and Main Results: At baseline, ILC2s were significantly higher in patients with asthma than in healthy subjects. At Day 8, ILC2s significantly increased from baseline in both groups, which was significantly higher in patients with asthma than in healthy subjects (all comparisons P < 0.05). In healthy subjects, ILC1s increased from baseline at Day 3 (P = 0.001), while in patients with asthma, ILC1s increased from baseline at Day 8 (P = 0.042). Patients with asthma had significantly higher ILC2:ILC1 ratios at baseline (P = 0.024) and Day 8 (P = 0.005). Increased ILC2:ILC1 ratio in patients with asthma correlated with clinical exacerbation severity and type 2 cytokines in nasal mucosal lining fluid. Conclusions: An ILC2-predominant inflammatory profile in patients with asthma was associated with increased severity and duration of rhinovirus infection compared with healthy subjects, supporting the potential role of ILC2s in the pathogenesis of virus-induced asthma exacerbations.
Authors: Peter W Heymann; Thomas A E Platts-Mills; Judith A Woodfolk; Larry Borish; Deborah D Murphy; Holliday T Carper; Mark R Conaway; John W Steinke; Lyndsey Muehling; W Gerald Teague; Joshua L Kennedy; Anne-Marie Irani; Matthew D McGraw; Stephen V Early; Lisa M Wheatley; Amy P Adams; Ronald B Turner Journal: J Allergy Clin Immunol Date: 2020-02-01 Impact factor: 10.793
Authors: Klaus F Rabe; Parameswaran Nair; Guy Brusselle; Jorge F Maspero; Mario Castro; Lawrence Sher; Hongjie Zhu; Jennifer D Hamilton; Brian N Swanson; Asif Khan; Jingdong Chao; Heribert Staudinger; Gianluca Pirozzi; Christian Antoni; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Neil M H Graham; Neil Stahl; George D Yancopoulos; Ariel Teper Journal: N Engl J Med Date: 2018-05-21 Impact factor: 91.245
Authors: Mario Castro; Jonathan Corren; Ian D Pavord; Jorge Maspero; Sally Wenzel; Klaus F Rabe; William W Busse; Linda Ford; Lawrence Sher; J Mark FitzGerald; Constance Katelaris; Yuji Tohda; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Asif Khan; Jingdong Chao; Renata Martincova; Neil M H Graham; Jennifer D Hamilton; Brian N Swanson; Neil Stahl; George D Yancopoulos; Ariel Teper Journal: N Engl J Med Date: 2018-05-21 Impact factor: 91.245
Authors: Christina A Christianson; Nicholas P Goplen; Iram Zafar; Chaoyu Irvin; James T Good; Donald R Rollins; Balachandra Gorentla; Weimin Liu; Magdalena M Gorska; HongWei Chu; Richard J Martin; Rafeul Alam Journal: J Allergy Clin Immunol Date: 2015-01-21 Impact factor: 10.793
Authors: Simon D Message; Vasile Laza-Stanca; Patrick Mallia; Hayley L Parker; Jie Zhu; Tatiana Kebadze; Marco Contoli; Gwen Sanderson; Onn M Kon; Alberto Papi; Peter K Jeffery; Luminita A Stanciu; Sebastian L Johnston Journal: Proc Natl Acad Sci U S A Date: 2008-09-03 Impact factor: 11.205
Authors: Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord Journal: N Engl J Med Date: 2009-03-05 Impact factor: 91.245
Authors: Janine Beale; Annabelle Jayaraman; David J Jackson; Sebastian L Johnston; Nathan W Bartlett; Jonathan D R Macintyre; Michael R Edwards; Ross P Walton; Jie Zhu; Yee Man Ching; Betty Shamji; Matt Edwards; John Westwick; David J Cousins; You Yi Hwang; Andrew McKenzie Journal: Sci Transl Med Date: 2014-10-01 Impact factor: 17.956
Authors: David J Jackson; Maria-Belen Trujillo-Torralbo; Jerico del-Rosario; Nathan W Bartlett; Michael R Edwards; Patrick Mallia; Ross P Walton; Sebastian L Johnston Journal: J Allergy Clin Immunol Date: 2015-03-13 Impact factor: 10.793
Authors: Katrien C De Grove; Sharen Provoost; Fien M Verhamme; Ken R Bracke; Guy F Joos; Tania Maes; Guy G Brusselle Journal: PLoS One Date: 2016-01-04 Impact factor: 3.240
Authors: Rod A Rahimi; Josalyn L Cho; Claudia V Jakubzick; Shabaana A Khader; Bart N Lambrecht; Clare M Lloyd; Ari B Molofsky; Sebastien Talbot; Catherine A Bonham; Wonder P Drake; Anne I Sperling; Benjamin D Singer Journal: Am J Respir Cell Mol Biol Date: 2022-07 Impact factor: 7.748
Authors: Aoife Cameron; Jaideep Dhariwal; Nadine Upton; Ismael Ranz Jimenez; Malte Paulsen; Ernie Wong; Maria-Belen Trujillo-Torralbo; Ajerico Del Rosario; David J Jackson; Michael R Edwards; Sebastian L Johnston; Ross P Walton Journal: Clin Exp Allergy Date: 2022-03-03 Impact factor: 5.401